International Journal on Magnetic Particle Imaging IJMPI
Vol. 12 No. 1 Suppl 1 (2026): Int J Mag Part Imag
https://doi.org/10.18416/IJMPI.2026.2603010
Proceedings Articles, ID 1024
In vivo MPI/BLI tracking of genome-edited-patient derived neural precursor cells in a transgenic ALS mouse model
Main Article Content
Copyright (c) 2026 Ali Shakeri-Zadeh, Asif Itoo, Shreyas Kuddannaya, Cristina Zivko, Vasiliki Mahairaki, Jeff Bulte

This work is licensed under a Creative Commons Attribution 4.0 International License.
Abstract
Amyotrophic lateral sclerosis (ALS) caused by superoxide dismutase 1 (SOD1) mutations may benefit from a gene-edited induced pluripotent stem cell (iPSC)-based therapy, provided cell fate after administration can be monitored precisely, non-invasively and longitudinally for effective optimization. This study evaluated tracking of neural precursor cells (NPCs) derived from gene-edited iPSCs using magnetic particle imaging (MPI) and bioluminescence imaging (BLI). Luciferase-expressing Nanoluc-NPCs were magnetically labeled and stereotaxically transplanted into the motor cortex of SOD1G93A transgenic mouse models. BLI confirmed luciferase activity and cell viability, while MPI enabled quantitative tracking of labeled cells in vivo. Regression analysis estimated an iron content of ~10 pg per cell, with MPI-derived cell numbers aligning closely with injected values. BLI signals persisted for two weeks, and behavioral testing revealed delayed disease progression for treated vs. non-treated controls. These results demonstrate successful non-invasive visualization and quantification of transplanted NPCs, supporting the use of MPI/BLI for imaging-guided cell therapies in ALS.
Article Details
References
[2] J.W.M. Bulte, et al., Quantitative “hot-spot” imaging of transplanted stem cells using superparamagnetic tracers and magnetic particle imaging. Tomography. 2015;1(2):91-98.
[3] E. Aguera-Morales, et al., 1. Aguera-Morales E, Fernández Sánchez VE, Navarro Mascarell G, Cabezas Rodríguez JA, Peña Toledo MÁ, Reyes Garrido V, et al. Adipose-derived mesenchymal stem cells for the treatment of Amyotrophic Lateral Sclerosis. A phase I/II safety and efficacy clinical trial. Frontiers in Neurology. 2025;16:1655124.
[4] A. Srivastava, et al., Serial in vivo imaging of transplanted allogeneic neural stem cell survival in a mouse model of amyotrophic lateral sclerosis. Experimental Neurology. 2017;289:96-102.